Impact of Off-Target AEs and Treatment Resistance on Evolving 1L Therapy Strategies for CLL

Author(s):

Catherine C. Coombs, MD,Brian T. Hill, MD, PhD

Javier Pinilla, MD, PhD, provides a brief overview of the changing CLL treatment landscape, discussing the influence of off-target adverse events and the development of treatment resistance on the evolution of BTK inhibitor therapy.

EP: 1.Current Front-Line Treatment Options for CLL in 2023

EP: 2.Exploring BTKi Monotherapy in CLL: Long-Term Updates from ELEVATE-TN and SEQUOIA

EP: 3.Strategies for Managing Treatment-Naïve CLL with High-Risk Features

Now Viewing

Impact of Off-Target AEs and Treatment Resistance on Evolving 1L Therapy Strategies for CLL

EP: 1.Current Front-Line Treatment Options for CLL in 2023

EP: 2.Exploring BTKi Monotherapy in CLL: Long-Term Updates from ELEVATE-TN and SEQUOIA

EP: 3.Strategies for Managing Treatment-Naïve CLL with High-Risk Features

EP: 4.Impact of Off-Target AEs and Treatment Resistance on Evolving 1L Therapy Strategies for CLL

EP: 5.Exploring the Role of BTKi-Based Combination Therapies for Front-line Management of CLL

EP: 6.Treatment Sequencing Strategies for R/R CLL: Impact of Prior 1L Therapy

EP: 7.Navigating BTKi Therapy in R/R CLL: Updates from ELEVATE-RR and ALPINE

EP: 8.Expert Perspectives on Navigating Treatment Selection with BTKis in CLL

EP: 9.Expert Insights into Navigating Cardiovascular Risks with BTKi Therapy

EP: 10.Treatment Resistance with Covalent BTKis: Translating Data into Clinical Practice

EP: 11.Role of Non-Covalent BTKis in R/R CLL: Updates from Ongoing BRUIN and Bellwave Trials

EP: 12.Emerging Data Surrounding Mechanisms of Resistance to Non-Covalent BTKis

EP: 13.Expert Insights into Investigation Therapies for CLL

EP: 14.Future Perspectives on the Treatment Landscape for CLL

Latest Conference Coverage